Enter inventor name

Paul Andrew Fitzpatrick

USPTO Granted Patents = 13 (Patent Applications = 2)

Average Co-Inventor Count = 5.5

ph-index = 6

Forward Citations = 254(Granted Patents)

Location History:

Albany, CA (US) (2002 - 2011)
Berkeley, CA (US) (2019 - 2022)

Company Filing History:

10 out of 135

Biomarin Pharmaceutical Inc.

The Scripps Research Institute

where one patent can have more than one assignee

Years Active: 2002-2022

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11505790 - Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof (2022-11-22),

2. 10221408 - Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof (2019-03-05),

3. 7888038 - Bak binding protein, DNA encoding the protein, and methods of use thereof (2011-02-15),

4. 7790433 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof (2010-09-07),

5. 7553653 - Variants and chemically-modified variants of phenylalanine ammonia-lyase (2009-06-30),

6. 7537923 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof (2009-05-26),

7. 7534595 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof (2009-05-19),

8. 7531341 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof (2009-05-12),

9. 7316915 - Bak binding protein, DNA encoding the protein, and methods of use thereof (2008-01-08),

10. 6972124 - Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme (2005-12-06),

11. 6866844 - Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme (2005-03-15),

12. 6569661 - Recombinant &agr;-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof (2003-05-27),

13. 6441135 - Bak binding protein, DNA encoding the protein, and methods of use thereof (2002-08-27),

Title: Paul Andrew Fitzpatrick: Innovator in Biochemical Engineering

Introduction

Paul Andrew Fitzpatrick is a notable inventor based in Albany, California. He has made significant contributions to the field of biochemical engineering, particularly through his work on phenylalanine ammonia-lyase variants. With a total of 13 patents to his name, Fitzpatrick's innovations have the potential to impact both industrial applications and therapeutic treatments.

Latest Patents

Fitzpatrick's latest patents focus on compositions of prokaryotic phenylalanine ammonia-lyase (PAL) variants and methods for their use. These variants exhibit enhanced phenylalanine-converting activity and reduced immunogenicity compared to wild-type PAL. The patents detail methods for the production, purification, formulation, and application of these compositions, which can be utilized for treating hyperphenylalaninemia, including phenylketonuria, as well as other disorders such as cancer.

Career Highlights

Throughout his career, Fitzpatrick has worked with prominent companies in the pharmaceutical industry, including BioMarin Pharmaceutical Inc. and Tanox, Inc. His work has been instrumental in advancing the understanding and application of biochemical processes in medical treatments.

Collaborations

Fitzpatrick has collaborated with esteemed colleagues such as Emil D. Kakkis and Daniel J. Wendt. These partnerships have contributed to the development of innovative solutions in the field of biochemistry.

Conclusion

Paul Andrew Fitzpatrick's contributions to biochemical engineering through his patents and collaborations highlight his role as a leading inventor in the industry. His work continues to pave the way for advancements in therapeutic applications and industrial processes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com